Edx Medical Group Plc Regulatory News (EDX.PL)

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

31 March 2025

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Company")

SHAREHOLDINGS UPDATE

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces that the Company has approved the issue of the following ordinary shares.

· 545,55 new ordinary shares of 1p each ("Additional Consideration Shares") in the Company to 13 former shareholders (including employees) of Hutano Diagnostics Ltd, ("Hutano") a 100%-owned subsidiary of the Company since September 2023. The issue of these Additional Consideration Shares to the relevant Hutano shareholders is dependent on the achievement of certain commercial milestones, in this instance the successful passing of filing of a patent covering proprietary Point of Care testing technology.

· 4,250,000 ordinary shares under the 2024-25 Company employee performance-related share option scheme, of which 3,750,000 are awarded to Mr Martin Walton, a director and deputy chair of the Company, under a performance schedule.

On March 20, EDX Medical announced the issue of 21,428, 571 new ordinary shares as a result of an equity fundraising round. The total number of shares issued has been revised to 21, 428,568.

Total Voting Rights

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that following the Fundraising, it will have 372,058,871 Ordinary Shares in issue, each share carrying the right to one vote. 

The above figure of 372,058,871 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The directors of EDX Medical accept responsibility for the contents of this announcement.

 Contacts:

​

Notes for Editors:

About EDX Medical Group 

EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

EDX Medical conducts product development, validation and distribution to ISO 13485 and provides PCR and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).